drugset / Trial / NCT07209865
68Ga-P16-093 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
NaSingle-groupOpen-labelDiagnostic
Summary
68Ga-P16-093 is a novel radiotracer targeting PSMA. In this study, we investigated the diagnostic efficacy of 68Ga-P16-093 PET imaging (PET/CT or PET/MRI) in patients with newly diagnosed, treatment-naive prostate cancer, and performed a head-to-head comparison with multi-parameter magnetic resonance imaging (mpMRI).
Timeline
- Start
- 2024-10-01
- Primary completion
- 2025-12-31
- Completion
- 2026-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-P16-093 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-P16-093 | Diagnostic / imaging agent | 148 mbq | Intravenous |